Nothing Special   »   [go: up one dir, main page]

EA201190138A1 - Производные фуропиримидиндиона в качестве модуляторов trpa1 - Google Patents

Производные фуропиримидиндиона в качестве модуляторов trpa1

Info

Publication number
EA201190138A1
EA201190138A1 EA201190138A EA201190138A EA201190138A1 EA 201190138 A1 EA201190138 A1 EA 201190138A1 EA 201190138 A EA201190138 A EA 201190138A EA 201190138 A EA201190138 A EA 201190138A EA 201190138 A1 EA201190138 A1 EA 201190138A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
trpa1
furopyrimidindion
subfamily
acting
Prior art date
Application number
EA201190138A
Other languages
English (en)
Inventor
Сачин Сундарлал Чаудхари
Абрахам Томас
Ниша Параг Патил
Неелима Кхайраткар-Джоши
Индранил Мухопадхяй
Original Assignee
Гленмарк Фармасьютикалс, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Гленмарк Фармасьютикалс, С.А. filed Critical Гленмарк Фармасьютикалс, С.А.
Publication of EA201190138A1 publication Critical patent/EA201190138A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

В заявке описаны новые сочлененные производные фуропиримидиндионов, которые являются модуляторами TRPA (действующего по механизму транзиторного рецепторного потенциала подсемейства А). В частности, описаны соединения, применимые для лечения или профилактики заболеваний, состояний и(или) нарушений, модулируемых TRPA1 (членом 1 действующего по механизму транзиторного рецепторного потенциала подсемейства А). Также описаны способы получения предложенных соединений, используемых для их синтеза промежуточных соединений, их фармацевтических композиций и способов лечения или профилактики заболеваний, состояний и(или) нарушений, модулируемых TRPA1.
EA201190138A 2009-03-23 2010-03-22 Производные фуропиримидиндиона в качестве модуляторов trpa1 EA201190138A1 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN665MU2009 2009-03-23
US17135509P 2009-04-21 2009-04-21
IN2213MU2009 2009-09-23
US25199409P 2009-10-15 2009-10-15
IN2906MU2009 2009-12-16
US29447010P 2010-01-12 2010-01-12
PCT/IB2010/000840 WO2010109329A1 (en) 2009-03-23 2010-03-22 Furopyrimidinedione derivatives as trpa1 modulators

Publications (1)

Publication Number Publication Date
EA201190138A1 true EA201190138A1 (ru) 2013-05-30

Family

ID=42780205

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201190138A EA201190138A1 (ru) 2009-03-23 2010-03-22 Производные фуропиримидиндиона в качестве модуляторов trpa1
EA201190139A EA022029B1 (ru) 2009-03-23 2010-03-23 Производные тиенопиримидиндиона в качестве модуляторов trpa1

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201190139A EA022029B1 (ru) 2009-03-23 2010-03-23 Производные тиенопиримидиндиона в качестве модуляторов trpa1

Country Status (23)

Country Link
US (4) US20120178766A1 (ru)
EP (3) EP2411395B1 (ru)
JP (2) JP2012521406A (ru)
KR (2) KR20110128898A (ru)
CN (3) CN102361874A (ru)
AP (1) AP2948A (ru)
AU (2) AU2010227225A1 (ru)
BR (2) BRPI1013705A2 (ru)
CA (2) CA2756535A1 (ru)
DK (3) DK2411395T3 (ru)
EA (2) EA201190138A1 (ru)
ES (3) ES2424341T3 (ru)
HK (2) HK1166073A1 (ru)
HU (1) HUE024538T2 (ru)
IL (2) IL215175A (ru)
MX (1) MX2011009822A (ru)
PE (2) PE20120834A1 (ru)
PL (3) PL2411395T3 (ru)
PT (3) PT2411395E (ru)
SG (4) SG184767A1 (ru)
SI (3) SI2411395T1 (ru)
WO (2) WO2010109329A1 (ru)
ZA (2) ZA201107650B (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2411395E (pt) 2009-03-23 2013-06-06 Glenmark Pharmaceuticals Sa Derivados de furopirimidinadiona como moduladores de trpa1
SG174402A1 (en) 2009-03-23 2011-10-28 Glenmark Pharmaceuticals Sa Fused pyrimidine-dione derivatives as trpa1 modulators
EP2655377B1 (en) 2010-12-20 2016-03-30 Glenmark Pharmaceuticals S.A. 2-amino-4-arylthiazole compounds as trpa1 antagonists
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
MX2013014679A (es) 2011-06-13 2014-07-14 Glenmark Pharmaceuticals Sa Tratamiento de trastornos respiratorios usando antagonistas de trpa1.
WO2012176105A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
WO2012176143A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a beta-2 agonist
WO2013014597A1 (en) 2011-07-25 2013-01-31 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a steroid
EP2787991A1 (en) 2011-12-05 2014-10-15 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
KR20150015488A (ko) * 2012-06-08 2015-02-10 그렌마크 파머수티칼스 에스. 아. 2-아미노-4-아릴티아졸 화합물의 아미드 및 그의 염
PT2903965T (pt) 2012-10-01 2017-06-06 Orion Corp Derivados de n-prop-2-inilcarboxamida e sua utilização como antagonistas de trpa1
WO2014203210A1 (en) * 2013-06-20 2014-12-24 Glenmark Pharmaceuticals S.A. Nanoparticulate formulation comprising a trpa1 antagonist
EP3057583A2 (en) 2013-10-15 2016-08-24 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
WO2016023831A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
WO2016023830A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
JP6573968B2 (ja) * 2014-08-11 2019-09-11 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． ＴＲＰＣ５調節因子としての、精神神経障害の処置のためのチエノおよびフロ［２，３−ｄ］ピリミジン−２，４［１Ｈ，３Ｈ］−ジオン誘導体
JP6695323B2 (ja) * 2014-08-11 2020-05-20 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピリド［３，４−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体
WO2016028325A1 (en) 2014-08-22 2016-02-25 Duke University Trpa1 and trpv4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2016042501A1 (en) 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
US11229628B2 (en) 2015-01-09 2022-01-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
CA3020364A1 (en) * 2016-04-07 2017-10-12 Duke University Small molecule dual-inhibitors of trpv4 and trpa1 for sanitizing and anesthetizing
CN110461838B (zh) * 2017-03-07 2022-05-06 豪夫迈·罗氏有限公司 噁二唑瞬时受体电位通道抑制剂
CN109422749B (zh) * 2017-08-21 2023-01-24 重庆医药工业研究院有限责任公司 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物
KR20230087531A (ko) 2020-10-14 2023-06-16 베링거 인겔하임 인터내셔날 게엠베하 Trpa1 억제제로서 테트라졸 유도체
EP4228755A1 (en) 2020-10-14 2023-08-23 Boehringer Ingelheim International GmbH Tetrazole derivatives as trpa1 inhibitors
CN114671875A (zh) * 2022-04-27 2022-06-28 成都施贝康生物医药科技有限公司 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途
CN114656480B (zh) * 2022-04-27 2024-01-26 成都施贝康生物医药科技有限公司 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (de) 1972-10-02 1974-04-11 Basf Ag 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
DK1107973T3 (da) * 1998-08-28 2004-02-23 Astrazeneca Ab Hidtil ukendte thieno(2,3-D)pyrimidindioner, fremgangsmåde til deres fremstilling og anvendelse deraf i terapi
ES2193839B1 (es) * 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
NZ540161A (en) * 2002-10-30 2008-03-28 Vertex Pharma Compositions useful as inhibitors of rock and other protein kinases
US6890923B2 (en) * 2002-12-16 2005-05-10 Astrazeneca Ab Compounds
AU2003290066A1 (en) 2002-12-18 2004-07-09 Novartis Ag Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
EP1657238A4 (en) 2003-08-22 2008-12-03 Takeda Pharmaceutical MERGED PYRIMIDINE DERIVATIVE AND USE THEREOF
JP2007522214A (ja) 2004-02-11 2007-08-09 スミスクライン・ビーチャム・コーポレイション Ｐｔｈアゴニスト
US20070196866A1 (en) 2004-03-13 2007-08-23 Irm Llc Modulators of ion channel trpa1
JPWO2006083005A1 (ja) * 2005-02-03 2008-06-26 武田薬品工業株式会社 縮合ピリミジン誘導体およびその用途
US20070032531A1 (en) * 2005-08-04 2007-02-08 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
ATE469148T1 (de) * 2005-11-08 2010-06-15 Organon Nv Zur behandlung von mit trpv1 in zusammenhang stehenden erkrankungen geeignete 2-(benzimidazol- 1yl)-n-(4-phenylthiazol-2-yl)acetamidderivate
WO2007054480A1 (en) * 2005-11-08 2007-05-18 N.V. Organon 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
US20070105920A1 (en) * 2005-11-08 2007-05-10 Akzo Nobel N.V. 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives
TWI423819B (zh) * 2005-12-22 2014-01-21 Hydra Biosciences Inc 用於調節ｔｒｐａ１功能之化合物
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
TW200836743A (en) 2007-01-29 2008-09-16 Xenon Pharmaceuticals Inc Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
CN103751194B (zh) * 2007-06-22 2018-01-05 海德拉生物科学公司 用于治疗病症的方法和组合物
KR101373794B1 (ko) * 2007-06-25 2014-03-13 샌디스크 테크놀로지스, 인코포레이티드 저장 소자들 사이에 개별적으로 제어가 가능한 차폐 플레이트들을 갖는 비휘발성 저장장치
US7951814B2 (en) 2008-06-17 2011-05-31 Glenmark Pharmaceuticals, S.A. Quinazolinedione derivatives as TRPA1 modulators
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
PL2411397T3 (pl) 2009-03-23 2013-10-31 Glenmark Pharmaceuticals Sa Pochodne izotiazolo-pirymidynodionu jako modulatory TRPA1
PT2411395E (pt) 2009-03-23 2013-06-06 Glenmark Pharmaceuticals Sa Derivados de furopirimidinadiona como moduladores de trpa1
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
AR076332A1 (es) 2009-04-21 2011-06-01 Boehringer Ingelheim Int Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
AP2012006192A0 (en) 2009-10-15 2012-04-30 Pfizer PyrroloÄ2,3-DÜ pyrimidine compounds.
US8440710B2 (en) 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG182480A1 (en) 2010-01-12 2012-08-30 Ab Science Thiazole and oxazole kinase inhibitors
DK2483255T3 (da) 2010-07-13 2014-01-20 Novartis Ag Oxazinderivater samt deres anvendelse ved behandling af neurologiske lidelser

Also Published As

Publication number Publication date
IL215175A0 (en) 2011-12-29
PT2411395E (pt) 2013-06-06
PE20120775A1 (es) 2012-06-27
PL2411395T3 (pl) 2013-10-31
EP2634191B1 (en) 2014-12-24
DK2411396T3 (da) 2013-08-05
JP5612070B2 (ja) 2014-10-22
US9474758B2 (en) 2016-10-25
AU2010227230A2 (en) 2011-10-27
SG174398A1 (en) 2011-10-28
WO2010109334A2 (en) 2010-09-30
IL215175A (en) 2014-01-30
BRPI1009381B8 (pt) 2021-05-25
HUE024538T2 (hu) 2016-01-28
US20150150876A1 (en) 2015-06-04
IL215177A0 (en) 2011-12-29
BRPI1009381A2 (pt) 2016-06-21
EA022029B1 (ru) 2015-10-30
EP2411396A2 (en) 2012-02-01
CN102361877B (zh) 2014-05-07
CN103755720A (zh) 2014-04-30
CN103755720B (zh) 2016-07-06
SG184769A1 (en) 2012-10-30
JP2012521406A (ja) 2012-09-13
EP2634191A1 (en) 2013-09-04
SI2634191T1 (sl) 2015-04-30
US8507503B2 (en) 2013-08-13
SG184767A1 (en) 2012-10-30
ES2424342T3 (es) 2013-10-01
WO2010109334A3 (en) 2010-11-25
ES2532386T3 (es) 2015-03-26
KR101524337B1 (ko) 2015-05-29
CN102361877A (zh) 2012-02-22
PL2634191T3 (pl) 2015-06-30
EP2411396B1 (en) 2013-05-29
SG174404A1 (en) 2011-10-28
ZA201107650B (en) 2012-07-25
CA2756536C (en) 2015-10-06
IL215177A (en) 2014-01-30
DK2634191T3 (en) 2015-03-23
AU2010227225A2 (en) 2011-10-06
HK1166073A1 (en) 2012-10-19
AU2010227230B2 (en) 2015-11-26
PL2411396T3 (pl) 2013-10-31
WO2010109329A1 (en) 2010-09-30
SI2411396T1 (sl) 2013-07-31
MX2011009822A (es) 2012-01-25
CA2756536A1 (en) 2010-09-30
ES2424341T3 (es) 2013-10-01
CA2756535A1 (en) 2010-09-30
KR20110128898A (ko) 2011-11-30
HK1166074A1 (en) 2012-10-19
AU2010227230A1 (en) 2011-09-22
DK2411395T3 (da) 2013-08-05
US8987278B2 (en) 2015-03-24
EP2411395B1 (en) 2013-05-29
US20120295924A1 (en) 2012-11-22
BRPI1009381B1 (pt) 2020-04-14
AU2010227225A1 (en) 2011-09-15
ZA201107649B (en) 2012-07-25
PE20120834A1 (es) 2012-07-25
EP2411395A1 (en) 2012-02-01
BRPI1013705A2 (pt) 2016-04-05
SI2411395T1 (sl) 2013-07-31
AP2948A (en) 2014-07-31
JP2012521407A (ja) 2012-09-13
CN102361874A (zh) 2012-02-22
EA201190139A1 (ru) 2012-03-30
PT2634191E (pt) 2015-03-04
US20120178766A1 (en) 2012-07-12
KR20120004422A (ko) 2012-01-12
AP2011005889A0 (en) 2011-10-31
PT2411396E (pt) 2013-06-06
US20130289054A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
EA201190138A1 (ru) Производные фуропиримидиндиона в качестве модуляторов trpa1
EA201390947A1 (ru) Соединения 2-амино-4-арилтиазола в качестве антагонистов trpa1
EA201190143A1 (ru) Сочлененные производные пиримидиндионов в качестве модуляторов trpa1
EA201190191A1 (ru) Изотиазоло-пиримидинедионовые производные в качестве модуляторов trpa1
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
WO2009118596A3 (en) Phthalimide derivatives as trpa1 modulators
EA201001371A1 (ru) Конденсированные пиримидиноновые соединения как модуляторы trpv3
EA200700489A1 (ru) Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
EA201171197A1 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
ATE478072T1 (de) Spiroimidazol-derivate als ppar-modulatoren
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
WO2010010435A3 (en) Fused oxazole and thiazole derivatives as trpms modulators
EA201000675A1 (ru) Производные хромана как модуляторы trpv3
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
EA201190086A1 (ru) Сочлененные производные имидазола в качестве антагониста trpv3
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
UA104861C2 (ru) Производные хромана как модуляторы trpv3
EA201390055A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОПИРАЗОЛО[3,4-b]АЗЕПИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ МЕТАБОТРОПНЫХ ГЛУТАМАТНЫХ РЕЦЕПТОРОВ